Objective: In this study, we evaluated the density of Mitochondrial complex 1 (MC1), sigma 1 receptor (s1R) and Synaptic Vesicle protein 2A (SV2A) in early de novo Parkinson’s disease (PD).

Background: MC1 and s1R are involved in the regulation of mitochondrial ATP production, and the SV2A is a molecular marker of the pre-synaptic terminals.

Method: Twelve early de novo Parkinson’s disease patients (10 males, 59.8±8.6 years old,  18.5±12.6 months since diagnosis) and 12 matched healthy controls (HC) underwent [18F]BCPP-EF, [11C]SA-4503, [11C]UCB-J PET, to quantify regional MC1, s1R and SV2A density respectively, using the total volume of distribution (VT) as the outcome parameter. Regions of interest (ROI) were defined on the individual T1 MRI using a standard atlas, except for the substantia nigra (SN), defined on a FGATIR MRI.

Results: One PD subject was excluded from the [11C]UCB-J analysis (VT > 3 SD higher than the group mean for a number of ROI). In the remaining 11 PD subjects, [11C]UCB-J VT was significantly reduced in the SN (-9.5%, P=0.01) and the putamen (-8.8%, P<0.05), with reductions in the caudate (-12.7%, P=0.13) and the ventral striatum (-6.6%, P=0.17) not reaching significance.  ROI volume,  [18F]BCPP-EF and [11C]SA-4503 VT differences did not reach significance (SN -12.1%, P=0.08 for [18F]BCPP-EF).

Conclusion: Our findings show evidence of reduced density of the SV2A in early de novo PD patients. Longitudinal studies will determine whether 18F]BCPP-EF, [11C]SA-4503 and [11C]UCB-J PET  are able to track disease progression.

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/mitochondrial-complex-1-sigma-1-receptor-and-synaptic-vesicle-protein-2a-density-in-early-de-novo-patients-with-parkinsons-disease-pilot-pet-data/